Rabbit anti-Human ACSL4 Polyclonal Antibody | anti-ACSL4 antibody

ACSL4, ID (ACSL4, ACS4, FACL4, LACS4, Long-chain-fatty-acid-CoA ligase 4, Long-chain acyl-CoA synthetase 4) (FITC)

Cat. Num. AAA6271115

• Gene Names: ACSL4; ACS4; FACL4; LACS4; MRX63; MRX68
• Reactivity: Human
• Applications: Immunofluorescence, Immunohistochemistry, Western Blot
• Purity: Purified by Protein G Affinity Chromatography.
• Synonyms: ACSL4; Polyclonal Antibody; ID (ACSL4; ACS4; FACL4; LACS4; Long-chain-fatty-acid-CoA ligase 4; Long-chain acyl-CoA synthetase 4) (FITC); Long-chain-fatty-acid--CoA ligase 4; Long-chain acyl-CoA synthetase 4; anti-ACSL4 antibody

• Host: Rabbit
• Reactivity: Human
• Clonality: Polyclonal
• Isotype: IgG
• Purity/Purification: Purified by Protein G Affinity Chromatography.
• Form/Format: Supplied as a liquid in PBS, pH 7.2. No preservative added. Labeled with Fluorescein Isothiocyanate (FITC).

• Applicable Applications for anti-ACSL4 antibody: Immunofluorescence (IF), FLISA, Immunohistochemistry (IHC), Western Blot (WB)
• Application Notes: IF: 1:10-50; FLISA: 1:1,000; IHC: 1:50-100; WB: 1:100-500; Applications are based on unconjugated antibody.
• Immunogen: ACSL4 (FACL4) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 244~274 amino acids from the center region of human FACL4.
• Conjugate: FITC
• Note: Preservative Free
• Special Handling: Light sensitive
• Preparation and Storage: Store product at 4 degree C if to be used immediately within two weeks. For long-term storage, aliquot to avoid repeated freezing and thawing and store at -20 degree C. Aliquots are stable at -20 degree C for 12 months after receipt. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: FITC conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Western Blot (WB)

(FACL4-E251 western blot analysis in HepG2 cell line lysates (35ug/lane).This demonstrates the FACL4 antibody detected the FACL4 protein (arrow).)

Immunofluorescence (IF)

(Confocal immunofluorescent analysis of ACSL4 (FACL4) Antibody (Center) with Hela cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green). DAPI was used to stain the cell nuclear (blue).)

Immunohistochemistry (IHC)

(Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)

Related Product Information for anti-ACSL4 antibody

Long chain acyl-CoA synthetase (LACS), or long chain fatty acid-CoA ligase (FACL), converts free long chain fatty acids into fatty acyl-CoA esters, key intermediates in the synthesis of complex lipids. The FACL4 gene encodes a form of LACS and is expressed in several tissues, including brain. FACL4 cDNA from brain encodes a gene product that shows preference for arachidonic acid as a substrate when expressed in mammalian cells.1 The sequence of the predicted 670-amino acid human protein is 97% identical to that of rat ACS4. FACL4 is highly expressed in adult human brain, especially in the cerebellum and hippocampus, similar to the mouse.2 A strong cytoplasmic staining was found in the Purkinje and granular cells of the cerebellum and the pyramidal layer of hippocampus, indicating that FACL4 is specifically expressed in neurons and not in glial cells. Two patients with Alport syndrome, elliptocytosis, and mental retardation carried a large deletion of the COL4A5 region that included FACL4.3 The absence of FACL4 might play a role in the development of mental retardation or other signs associated with Alport syndrome. Two point mutations, 1 missense and 1 splice site change, were reported in the FACL4 gene in 2 families with nonspecific mental retardation.2 Analysis of enzymatic activity in lymphoblastoid cell lines of affected individuals revealed low levels compared with normal cells, indicating that both mutations are null mutations.

Product Categories/Family for anti-ACSL4 antibody

Antibodies; Enzymes; Synthase

NCBI and Uniprot Product Information

• NCBI GI #: 4758332
• NCBI GeneID: 2182
• NCBI Accession #: NP_004449.1
• NCBI GenBank Nucleotide #: NM_004458.2
• UniProt Accession #: O60488; O60848; O60849; Q5JWV8; D3DUY2
• Molecular Weight: 74,436 Da
• NCBI Official Full Name: long-chain-fatty-acid--CoA ligase 4 isoform 1
• NCBI Official Synonym Full Names: acyl-CoA synthetase long-chain family member 4
• NCBI Official Symbol: ACSL4
• NCBI Official Synonym Symbols: ACS4; FACL4; LACS4; MRX63; MRX68
• NCBI Protein Information: long-chain-fatty-acid--CoA ligase 4; LACS 4; acyl-CoA synthetase 4; lignoceroyl-CoA synthase; long-chain acyl-CoA synthetase 4; long-chain fatty-acid-Coenzyme A ligase 4; fatty-acid-Coenzyme A ligase, long-chain 4
• UniProt Protein Name: Long-chain-fatty-acid--CoA ligase 4
• UniProt Gene Name: ACSL4
• UniProt Synonym Gene Names: ACS4; FACL4; LACS4; LACS 4
• UniProt Entry Name: ACSL4_HUMAN

NCBI Description

The protein encoded by this gene is an isozyme of the long-chain fatty-acid-coenzyme A ligase family. Although differing in substrate specificity, subcellular localization, and tissue distribution, all isozymes of this family convert free long-chain fatty acids into fatty acyl-CoA esters, and thereby play a key role in lipid biosynthesis and fatty acid degradation. This isozyme preferentially utilizes arachidonate as substrate. The absence of this enzyme may contribute to the mental retardation or Alport syndrome. Alternative splicing of this gene generates 2 transcript variants. [provided by RefSeq, Jul 2008]

Uniprot Description

ACSL4: Activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. Preferentially uses arachidonate and eicosapentaenoate as substrates. Defects in ACSL4 are the cause of mental retardation X- linked type 63 (MRX63). Mental retardation is a mental disorder characterized by significantly sub-average general intellectual functioning associated with impairments in adaptative behavior and manifested during the developmental period. Non- syndromic mental retardation patients do not manifest other clinical signs. Defects in ACSL4 are involved in Alport syndrome with mental retardation midface hypoplasia and elliptocytosis (ATS-MR). A X-linked contiguous gene deletion syndrome characterized by glomerulonephritis, deafness, mental retardation, midface hypoplasia and elliptocytosis. Belongs to the ATP-dependent AMP-binding enzyme family. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Ligase; EC 6.2.1.3; Membrane protein, integral; Lipid Metabolism - fatty acid

Chromosomal Location of Human Ortholog: Xq22.3-q23

Cellular Component: peroxisomal membrane; mitochondrial outer membrane; endoplasmic reticulum membrane; cell soma; membrane; cytoplasm; integral to membrane; lipid particle

Molecular Function: arachidonate-CoA ligase activity; very-long-chain-fatty-acid-CoA ligase activity; ATP binding; long-chain-fatty-acid-CoA ligase activity

Biological Process: embryonic process involved in female pregnancy; lipid biosynthetic process; triacylglycerol biosynthetic process; cellular lipid metabolic process; lipid metabolic process; long-chain fatty acid metabolic process; negative regulation of prostaglandin secretion; positive regulation of cell growth; response to nutrient; fatty acid transport

Disease: Mental Retardation, X-linked 63